NeoClone Gets $750,000 Grant
NeoClone Biotechnology is getting a big boost toward developing a product that may be able to identify ovarian cancer in its early stages. The National Institutes of Health's National Cancer Institute is granting the Madison biotech company a $750,000 Phase II contract to continue its research into biological markers that signal ovarian cancer.